[go: up one dir, main page]

BR9916323A - Integrin inhibitors alfavbeta6 - Google Patents

Integrin inhibitors alfavbeta6

Info

Publication number
BR9916323A
BR9916323A BR9916323-3A BR9916323A BR9916323A BR 9916323 A BR9916323 A BR 9916323A BR 9916323 A BR9916323 A BR 9916323A BR 9916323 A BR9916323 A BR 9916323A
Authority
BR
Brazil
Prior art keywords
xaa
peptides
alfavbeta6
integrin
integrin inhibitors
Prior art date
Application number
BR9916323-3A
Other languages
Portuguese (pt)
Inventor
Beate Diefenbach
Alfred Jonczyk
Sabine Kraft
Ray Mehta
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR9916323A publication Critical patent/BR9916323A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Patente de Invenção: "INIBIDORES DA INTEGRINA ALFA~v~BETA~ 6~". A invenção descreve novos peptídeos que, comoligandos da integrina <244>~ v~,<225>~ 6~, são biologicamenteativos. Todos estes peptídeos têm um motif estrutural comum, asaber - Asp Leu Xaa Xaa Leu -, ou em uma forma preferida - ArgXaa Asp Leu Xaa Xaa Leu Arg -, onde Xaa é qualquer resíduo deaminoácido desejado. Os peptídeos de acordo com a invençãopodem ser empregados como inibidores eficazes do receptor deintegrina <244>~ v~<225>~ 6~ e desse modo para o tratamentode várias doenças e laudos patológicos.Invention Patent: "ALPHA INTEGRIN INHIBITORS ~ v ~ BETA ~ 6 ~". The invention describes new peptides which, as ligands of the integrin <244> ~ v ~, <225> ~ 6 ~, are biologically active. All of these peptides have a common structural motif, known - Asp Leu Xaa Xaa Leu -, or in a preferred form - ArgXaa Asp Leu Xaa Xaa Leu Arg -, where Xaa is any desired amino acid residue. The peptides according to the invention can be used as effective inhibitors of the deintegrin receptor <244> ~ v ~ <225> ~ 6 ~ and thus for the treatment of various diseases and pathological reports.

BR9916323-3A 1998-12-19 1999-12-11 Integrin inhibitors alfavbeta6 BR9916323A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19858857 1998-12-19
PCT/EP1999/009842 WO2000037487A1 (en) 1998-12-19 1999-12-11 αvβ6 INTEGRIN INHIBITORS

Publications (1)

Publication Number Publication Date
BR9916323A true BR9916323A (en) 2001-10-30

Family

ID=7891834

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916323-3A BR9916323A (en) 1998-12-19 1999-12-11 Integrin inhibitors alfavbeta6

Country Status (10)

Country Link
EP (1) EP1140989A1 (en)
JP (1) JP2002533064A (en)
CN (1) CN1335853A (en)
AR (1) AR022395A1 (en)
BR (1) BR9916323A (en)
CA (1) CA2355874A1 (en)
CZ (1) CZ20012212A3 (en)
NO (1) NO20013013D0 (en)
WO (1) WO2000037487A1 (en)
ZA (1) ZA200105929B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19929410A1 (en) * 1999-06-26 2000-12-28 Merck Patent Gmbh New octapepide compounds as alpha v beta 6 integrin inhibitors useful for treating and diagnosing heart disease, tumors, osteoporosis, fibrosis, inflammation, infection and psoriasis
DE19933173A1 (en) * 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclic peptide derivatives as inhibitors of the integrin alpha¶v¶beta¶6¶
MY147019A (en) 2002-03-13 2012-10-15 Biogen Idec Inc Anti-alpha v beta 6 antibodies
CA2515127A1 (en) 2003-02-06 2004-08-19 Alfred Jonczyk Peptidic sulfonamides
CN102875681A (en) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 Anti-alpha v beta 6 antibodies and uses thereof
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
CN101563105B (en) 2006-07-10 2013-01-23 拜奥根Idec马萨诸塞公司 Compositions and methods for inhibiting smad4-deficient cancer
WO2008112004A2 (en) 2006-08-03 2008-09-18 Astrazeneca Ab ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
AU2007354317A1 (en) * 2006-10-19 2008-12-04 Biogen Idec Ma Inc. Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6
WO2009093251A2 (en) * 2008-01-24 2009-07-30 Gavish-Galilee Bio Applications Ltd Reovirus vaccine based on sigma c protein sequence
WO2014007547A1 (en) * 2012-07-03 2014-01-09 Il Yang Pharm. Co.,Ltd. Novel peptides and use thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
BR112019017929A2 (en) 2017-02-28 2020-05-19 Morphic Therapeutic Inc integrin (alpha-v) (beta-6) inhibitors
EP4147698A1 (en) 2017-02-28 2023-03-15 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
ES3019404T3 (en) 2018-08-29 2025-05-20 Morphic Therapeutic Inc Integrin inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219515A (en) * 1987-02-10 1989-09-27 Wellcome Found Fusion proteins comprising influenza virus ha and a nonnatural antigenic epitope

Also Published As

Publication number Publication date
EP1140989A1 (en) 2001-10-10
CN1335853A (en) 2002-02-13
ZA200105929B (en) 2003-03-18
WO2000037487A1 (en) 2000-06-29
CA2355874A1 (en) 2000-06-29
WO2000037487A8 (en) 2001-03-29
NO20013013L (en) 2001-06-18
AR022395A1 (en) 2002-09-04
JP2002533064A (en) 2002-10-08
NO20013013D0 (en) 2001-06-18
CZ20012212A3 (en) 2001-09-12

Similar Documents

Publication Publication Date Title
BR9916323A (en) Integrin inhibitors alfavbeta6
CA1223198A (en) Repair of tissue in animals
FI911780A0 (en) THERAPEUTIC PEPTIDER.
BR0009964A (en) Artificial peptides with surface activity and their use in the preparation of artificial surfactant
BR9711805A (en) Compounds and methods for providing pharmacologically active preparations and use
DK0910647T3 (en) Human DNase in hyperactive variants
BR0007663A (en) Acyl derivatives for use in the treatment of diseases related to vla-4
BR9913705A (en) Methods for the treatment of multiple myeloma and bone tissue resorption induced by myeloma using integrin antagonists
BR9710615A (en) Use of an agent in the manufacture of a medication for the treatment of bone metabolic disease, and, bone anti-absorption agent.
PT99566A (en) METHOD FOR THE PREPARATION OF FRAGMENTS OF THE FIBROBLAST GROWTH FACTOR
US7229788B1 (en) Protease susceptibility II
ATE455792T1 (en) NEW PHOSPHATE BINDING PROTEIN, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USE THEREOF
DE69736276D1 (en) HUMAN DNASE RESISTANT AGAINST ACTININHIBITORS
BRPI0415431A (en) processes and compositions for altering seed phenotypes
BR0113147A (en) Stress Proteins and Peptides and Methods of Using Them
ATE405649T1 (en) INHIBITOR FOR THE DIAGNOSIS AND TREATMENT OF HAEMOPHILIA A PATIENTS
YU60199A (en) New bpc peptide salts with organo-protective activity,the process for their preparation and their use in therapy
NO20016341L (en) Inhibitors for the integrin &lt;alfa&gt; v &lt;beta&gt; 6
ATE540968T1 (en) ALPHA FETOPROTEIN PEPTIDES AND USES THEREOF
Pirollet et al. Identification of a specific endogenous inhibitor of a casein kinase (G type) in bovine adrenal cortex as a glycosaminoglycan mixture
BR0014803A (en) Peptide, pharmaceutical composition, use of one or more of the peptides, and diagnostic composition
NO20004393L (en) Use of CD137 to promote proliferation of peripheral monocytes
Wirtz et al. In vivo and in vitro noncovalent association of excised alpha 1 (I) amino-terminal propeptides with mutant pN alpha 2 (I) collagen chains in native mutant collagen in a case of Ehlers-Danlos syndrome, type VII.
DE60141948D1 (en) COMPOSITIONS TO BE USED TO CONTROL PARKINACTIVITY
BR0202157A (en) Peptide obtained from scorpion venom for use as hypotensive agent

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6O, 7O ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.